Gilead Sciences, Inc. (GILD)

In the past six months, Gilead Sciences' stock has gained 27.2%. Key events impacting the stock price include the FDA approval of Yeztugo (lenacapavir), positive clinical trial results for Trodelvy, Q1 2025 financial results beating consensus, recent instances of insider selling, and competitive headwinds for the Cell Therapy franchise and Trodelvy.

Gilead Sciences' revenue exhibits a noticeable seasonality, with lower earnings typically observed in the first half of the year compared to the last two quarters. While the income announced in the first and second quarters of each year could previously diverge by up to 10%, this divergence has been around 4% (negative or positive) since 2019. Despite these seasonal fluctuations, products like Biktarvy and Descovy continue to show strong demand.

Gilead Sciences, Inc. is an American biopharmaceutical company focused on researching, developing, and commercializing medicines for life-threatening diseases. It operates in the healthcare sector, specifically in biotechnology and pharmaceutics, with core business segments focused on antiviral drugs for HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. Gilead has expanded its portfolio to include treatments for oncology, liver diseases, hematology, and inflammatory and respiratory diseases. Major products include HIV/AIDS treatments and prevention, COVID-19 treatment, viral hepatitis treatments, oncology products, and other products.

Gilead Sciences is headquartered in Foster City, California, and operates in more than 35 countries worldwide. The United States accounts for 71.6% of net sales, Europe for 16.1%, and other regions for 12.3%. The company has made key emerging market investments in China, India, and Brazil. Gilead also has a facility in Oceanside, California, for clinical manufacturing and process development.

Gilead Sciences has been recognized for its commitment to corporate responsibility and sustainability, being named one of America's Most JUST Companies and included in the Dow Jones Sustainability World Index. The company focuses on stakeholder engagement, expanding health equity globally, increasing access to medicines in low- and lower-middle-income countries, and fostering an inclusive workplace. However, Gilead's brand reputation in terms of access to medicine has faced some scrutiny, with the company performing below average in Governance of Access and increasing the price of AmBisome by 40% per vial in 2024.

Gilead Sciences' ownership structure is primarily institutional, with approximately 83.64% of the company's stock held by institutional shareholders, 1.11% by Gilead Sciences insiders, and 15.25% by retail investors. Institutional investors hold a significant influence over the company's share price, with 13 investors holding a majority stake of 50%. Vanguard Group Inc. is the largest individual shareholder, owning 9.44% of the company's shares.